OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
7-Point Dermoscopy ChecklistAJCC Melanoma Staging (8th Ed)ALDEN Algorithm (Drug Causality for SJS/TEN)BWH High-Risk SCC StagingBody Surface Area (BSA)Breslow Thickness and Clark LevelDLQIEASI ScoreMSK Melanoma NomogramMelanoma RiskPASI ScorePOEM (Patient-Oriented Eczema Measure)RegiSCAR Criteria for DRESSSCORADSCORTENmPASI (Modified PASI)

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • To triage clinically suspicious pigmented skin lesions using dermoscopy.
  • Helps differentiate melanoma from benign melanocytic nevi at the bedside.
CLINICAL INSIGHT

How it Works

Major Criteria (2 points each)

  • Atypical pigment network: Thickened lines, irregular holes.
  • Blue-white veil: Irregular, structureless blue pigmentation with an overlying white "ground-glass" haze.
  • Atypical vascular pattern: Linear-irregular or dotted vessels not clearly arrayed.

Minor Criteria (1 point each)

  • Irregular streaks: Radial streaming or pseudopods at the periphery.
  • Irregular pigmentation: Structureless areas of brown/black/gray not centrally located.
  • Irregular dots/globules: Varying sizes and shapes, distributed asymmetrically.
  • Regression structures: White scar-like areas and/or blue pepper-like granules.
CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

  • A score of ≥ 3 is highly suspicious for melanoma and mandates excision/biopsy.
  • Very high sensitivity, but moderate specificity; benign lesions (like dysplastic nevi or Spitz nevi) can occasionally score ≥ 3.
CLINICAL INSIGHT

Next Steps

Clinical Action

If score ≥ 3, proceed with excisional biopsy (with 1-3mm margins). Avoid punch biopsies or shave biopsies if melanoma is suspected, as this alters Breslow depth staging.

CLINICAL INSIGHT

Evidence Base

Primary Reference

SCORAD

SCORAD Index: Unified assessment of Atopic Dermatitis severity (Area, Intensity, Symptoms).
0%0%100%

erythema

edema

crusting

excoriation

lichenification

dryness

0010
0010
EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Evaluating the severity of atopic dermatitis (eczema) objectively.
  • Monitoring disease progression and treatment response over time.
  • Standardized reporting in clinical trials for atopic dermatitis therapies.
CLINICAL INSIGHT

How it Works

Formula

Variables

  • A: Extent of disease as percentage of Body Surface Area (BSA) affected (0-100).
  • B: Intensity of 6 specific morphologic lesions (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, and dryness/xerosis) graded 0-3. Max 18.
  • C: Subjective symptoms (pruritus and sleep loss) over the last 3 days, graded 0-10 on VAS. Max 20.
CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

  • Dryness (xerosis) is evaluated ONLY on uninvolved skin areas.
  • It combines both objective physician assessment and subjective patient-reported outcomes, making it very comprehensive.
  • A score > 50 indicates severe atopic dermatitis.
CLINICAL INSIGHT

Next Steps

Interpretation

  • < 25: Mild disease.
  • 25 - 50: Moderate disease.
  • > 50: Severe disease. Consider escalation to systemic immunosuppression or biologics.